Paul T. Kim is Principal at Kendall Square Policy Strategies LLC, where he advises Fortune 500 companies, life science trade associations, national patient advocates, and emerging biotech firms on FDA and public health policy in the U.S., Europe, and Korea. He specializes in legislative and regulatory strategy, policy reform, federal funding, and public-private partnerships (P3s).

With over 30 years of experience in Washington, DC, Paul has expertise in drug and device law, rare disease innovation, public health and immunization policy, biodefense policy, and congressional oversight & investigations. He has represented biotechnology, pharmaceutical, and medical technology companies before the FDA, CMS, HHS ASPR/BARDA, and Congress.

Previously, Paul spent 20 years as a partner at Foley Hoag LLP, where he co-chaired the FDA and government strategies practices. Before that, he held senior government roles, serving as Deputy Staff Director for Health for Senator Edward Kennedy, Counsel to Congressman Henry Waxman, and a Policy Analyst at the FDA. He has also worked at amfAR (American Foundation for AIDS Research) and Ciba-Geigy Ltd.

Paul serves on the Board of Directors for Friends of Cancer Research and holds advisory roles with the National Organization for Rare Disorders, No Patient Left Behind, Sjögren’s Foundation, and Nucleate Philadelphia & Boston.

He holds a JD from Georgetown University Law Center, an MPP in Science and Technology from Harvard Kennedy School, and an AB cum laude from Harvard College.

Paul has been recognized on the Massachusetts Pro Bono High Honor Roll (2019–2022) and named among Best Lawyers in America and Super Lawyers (2010–2023). His work has been featured in publications such as Milbank Quarterly and Health Affairs Forefront, and he has spoken at leading policy conferences and webinars.